[1]王小瑞,郑献召,韩凯,等.沙格列汀对2型糖尿病伴缺血性脑卒中患者血糖水平及认知功能的影响[J].新乡医学院学报,2022,39(12):1163-1167.[doi:10.7683/xxyxyxb.2022.12.012]
　WANG Xiaorui,ZHENG Xianzhao,HAN Kai,et al.Effect of saxagliptin on blood glucose level and cognitive function of patients with type 2 diabetes and ischemic stroke[J].Journal of Xinxiang Medical University,2022,39(12):1163-1167.[doi:10.7683/xxyxyxb.2022.12.012]
点击复制

沙格列汀对2型糖尿病伴缺血性脑卒中患者血糖水平及认知功能的影响
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年12
页码:
1163-1167
栏目:
临床研究
出版日期:
2022-12-05

文章信息/Info

Title:
Effect of saxagliptin on blood glucose level and cognitive function of patients with type 2 diabetes and ischemic stroke
作者:
王小瑞1; 郑献召2; 韩凯3; 刘海燕4
（1．焦作市人民医院全科医学科，河南　焦作　454150；2.焦作市人民医院神经内科一区,河南　焦作　454150;3.焦作市人民医院神经内科三区,河南　焦作　454150;4.焦作市人民医院神经内科二区,河南　焦作　454150）
Author(s):
WANG Xiaorui1; ZHENG Xianzhao2; HAN Kai3; LIU Haiyan4
(1.Department of General Medicine,Jiaozuo People′s Hospital,Jiaozuo 454150,Henan Province,China;2.Department of Neurology Ⅰ,Jiaozuo People′s Hospital,Jiaozuo 454150,Henan Province,China;3.Department of Neurology Ⅲ,Jiaozuo People′s Hospital,Jiaozuo 454150,Henan Province,China;4.Department of Neurology Ⅱ,Jiaozuo People′s Hospital,Jiaozuo 454150,Henan Province,China)
关键词:
2型糖尿病; 缺血性脑卒中; 沙格列汀; 糖化血红蛋白; 蒙特利尔认知评估量表
Keywords:
type 2 diabetes; ischemic stroke; saxagliptin; glycosylated hemoglobin; montreal cognitive assessment scale
分类号:
R587.1
DOI:
10.7683/xxyxyxb.2022.12.012
文献标志码:
A
摘要:
目的　探讨沙格列汀对2型糖尿病伴缺血性脑卒中患者血糖水平及认知功能的影响。方法　选择2018年11月至2020年11月焦作市人民医院收治的150例2型糖尿病伴缺血性脑卒中患者为研究对象。将患者随机分为观察组和对照组，每组75例。2组患者均给予常规治疗，对照组患者在常规治疗基础上给予二甲双胍治疗，观察组患者在常规治疗基础上给予沙格列汀治疗，均连续治疗3个月。比较2组患者治疗前后的血糖指标［空腹血糖（FBG）、餐后2 h血糖（2 h PBG）、糖化血红蛋白（HbA1c）］、血糖漂移幅度［日内平均血糖漂移幅度（MAGE）、日间血糖漂移幅度（MODD）、平均餐后血糖漂移幅度（MPPGE）、血糖水平标准差（SDBG）］、肾功能指标［血肌酐（SCr）、血尿素氮（BUN）、血清胱抑素C（Cys C）］、认知功能［蒙特利尔认知评估量表（MoCA）评分］及不良反应发生情况。结果　治疗前2组患者FBG、2 h PBG、HbA1c比较差异均无统计学意义（P>0.05）；2组患者治疗后FBG、2 h PBG、HbA1c水平均低于治疗前（P<0.05）；治疗后，2组患者的FBG、2 h PBG、HbA1c水平比较差异均无统计学意义（P>0.05）。治疗前2组患者的MAGE、MODD、MPPGE、SDBG比较差异均无统计学意义（P>0.05）；治疗后，2组患者的MAGE、MODD、MPPGE、SDBG均低于治疗前（P<0.05），且观察组患者的MAGE、MODD、MPPGE、SDBG低于对照组（P<0.05）。治疗前2组患者的SCr、BUN、Cys C水平比较差异均无统计学意义（P>0.05）；2组患者治疗后的SCr、BUN、Cys C水平均低于治疗前（P<0.05）；治疗后，2组患者的SCr、BUN、Cys C水平比较差异均无统计学意义（P>0.05）。治疗前2组患者的MoCA评分比较差异无统计学意义（P>0.05）；2组患者治疗后的MoCA评分均高于治疗前（P<0.05）；治疗后，2组患者的MoCA评分比较差异无统计学意义（P>0.05）。观察组和对照组患者不良反应发生率分别为12.00%（9/75）、14.67%（11/75），2组患者的不良反应发生率比较差异无统计学意义（χ2=0.231，P>0.05）。结论　沙格列汀能有效降低2型糖尿病伴缺血性脑卒中患者的血糖水平、改善患者的肾功能和认知功能，获得与二甲双胍相同的治疗效果，其对血糖漂移幅度的改善作用更强，且安全性佳。
Abstract:
Objective　To investigate the effect of saxagliptin on blood glucose level and cognitive function of patients with type 2 diabetes and ischemic stroke.Methods　A total of 150 patients with type 2 diabetes and ischemic stroke admitted to Jiaozuo People′s Hospital from November 2018 to November 2020 were selected as the research objects,and the patients were randomly divided into the observation group (n=75) and the control group (n=75).All patients were given conventional treatment.Based on conventional treatment,the patients in the control group were treated with metformin,and the patients in the observation group were treated with saxagliptin for 3 months continuously.The blood glucose indexes ［fasting blood glucose (FBG),2 h postprandial blood glucose (2 h PBG),glycosylated hemoglobin (HbA1c)］,blood glucose drift amplitude ［mean amplitude of glycemic excursion (MAGE),mean of daily difference (MODD),mean postprandial glucose excursion (MPPGE),standard deviation of blood glucose(SDBG)］,renal function indexes ［serum creatinine (SCr),blood urea nitrogen (BUN),serum cystatin C (Cys C)］,cognitive function index ［montreal cognitive assessment scale (MoCA) score］ and the occurrence of adverse reactions of patients were compared between the two groups before and after treatment.Results　There was no significant difference in the FBG,2 h PBG and HbA1c levels of patients between the two groups before treatment(P>0.05).The FBG,2 h PBG and HbA1c levels of patients after treatment were significantly lower than those before treatment in the two groups (P<0.05).There was no significant difference in the FBG,2 h PBG and HbA1c levels of patients between the two groups after treatment(P>0.05).There was no significant difference in the MAGE,MODD,MPPGE,SDBG of patients between the two groups before treatment(P>0.05).The MAGE,MODD,MPPGE,SDBG of patients after treatment were significantly lower than those before treatment in the two groups (P<0.05).After treatment,the MAGE,MODD,MPPGE,SDBG of patients in the observation group were significantly lower than those in the control group (P<0.05).There was no significant difference in the SCr,BUN and Cys C of patients between the two groups before treatment(P>0.05).The SCr,BUN and Cys C levels of patients after treatment were significantly lower than those before treatment in the two groups (P<0.05).There was no significant difference in the SCr,BUN and Cys C levels of patients between the two groups after treatment(P>0.05).There was no significant difference in the MoCA scores of patients between the two groups before treatment(P>0.05).The MoCA scores of patients after treatment were significantly higher than those before treatment (P<0.05).There was no significant difference in the MoCA scores of patients between the two groups after treatment(P>0.05).The incidence of adverse reactions of patients in the observation group and the control group were 12.00% (9/75) and 14.67% (11/75),respectively;there was no significant difference in the incidence of adverse reactions between the two groups（χ2=0.231，P>0.05）.Conclusion　Saxagliptin can effectively reduce the blood glucose level of type 2 diabetes patients with ischemic stroke,improve the renal function and cognitive function of patients,and obtain the same therapeutic effect as metformin,it has a stronger effect in the improvement of blood glucose drift and is safe.

参考文献/References:

［1］　PETERSMANN A,MLLER-WIELAND D,MLLER UA,et al.Definition,classification and diagnosis of diabetes mellitus［J］.Exp Clin Endocrinol Diabetes,2019,127(S 01):S1-S7.
［2］　ZHENG Y,LEY S H,HU F B.Global aetiology and epidemiology of type 2 diabetes mellitus and its complications［J］.Nat Rev Endocrinol,2018,14(2):88-98.
［3］　FURTADO R H M,BONACA M P,RAZ I,et al.Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction［J］.Circulation,2019,139(22):2516-2527.
［4］　ZHOU Z,LINDLEY R I,R A°DHOLM K,et al.Canagliflozin and stroke in type 2 diabetes mellitus［J］.Stroke,2019,50(2):396-404.
［5］　MEN P,LI X T,TANG H L,et al.Efficacy and safety of saxagliptin in patients with type 2 diabetes:a systematic review and meta-analysis［J］.PLoS One,2018,13(5):e0197321.
［6］　ARAKI E,TANAKA A,INAGAKI N,et al.Diagnosis,prevention,and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes：a consensus statement jointly from the Japanese circulation society and the Japan diabetes society［J］.Circ J,2020,85(1):82-125.
［7］　陈蕊华,蒋晓真,隋海晶,等.2型糖尿病患者脑白质病变与轻度认知功能障碍的相关性研究［J］.中国糖尿病杂志,2020,28(5):331-335.
CHEN R H,JIANG X Z,SUI H J,et al.Correlations between white matter lesions and mild cognitive impairment in patients with type 2 diabetes mellitus［J］.Chin J Diabetes,2020,28(5):331-335.
［8］　LAU L H,LEW J,BORSCHMANN K,et al.Prevalence of diabetes and its effects on stroke outcomes:a meta-analysis and literature review［J］.J Diabetes Investig,2019,10(3):780-792.
［9］　CHEN W,PAN Y,JING J,et al.Recurrent stroke in minor ischemic stroke or transient ischemic attack with metabolic syndrome and/or diabetes mellitus［J］.J Am Heart Assoc,2017,6(6):e005446.
［10］　ZOU C Y,LIU X K,SANG Y Q,et al.Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes:a meta-analysis［J］.Medicine (Baltimore),2019,98(49):e18245.
［11］　ORIME K,TERAUCHI Y.Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus［J］.Expert Opin Pharmacother,2020,21(17):2101-2114.
［12］　王进红,蒋晓鸣.沙格列汀治疗2型糖尿病的临床疗效观察［J］.浙江医学,2018,40(8):875-877.
WANG J H,JIANG X M.Clinical observation on the therapeutic effect of shagliptin on type 2 diabetes［J］.Zhejiang Med J，2018,40(8):875-877.
［13］　邱文娟,杨雪梅,丁韬.沙格列汀改善2型糖尿病患者血压效果的研究［J］.山西医药杂志,2016,45(6):636-639.
QIU W J,YANG X M,DING T.Evaluation of the efficacy of saxagliptin on improving blood pressure of patients with type 2 diabetes［J］.Shanxi Med J,2016,45(6):636-639.
［14］　MAGIS Q,GAUDY-MARQUESTE C,BASIRE A,et al.Diabetes and blood glucose disorders under anti-PD1［J］.J Immunother,2018,41(5):232-240.
［15］　GAULT V A,LENNOX R,FLATT P R.Sitagliptin,a dipeptidyl peptidase-4 inhibitor,improves recognition memory,oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline［J］.Diabetes Obes Metab,2015,17(4):403-413.
［16］　夏威,张菱,虎子颖.西格列汀对老年2型糖尿病轻度认知障碍患者血糖漂移和认知功能的影响研究［J］.中国全科医学,2018,21(31):60-63.
XIA W,ZHANG L,HU Z Y.Effect of sitagliptin on glycemic excursion and cognitive function among elderly type 2 diabetic patients with mild cognitive impairment［J］.Chin Gen Pract,2018,21(31):60-63.
［17］　BIESSELS G J,VERHAGEN C,JANSSEN J,et al.Effect of linagliptin on cognitive performance in patients with type 2 diabetes and cardiorenal comorbidities:the CARMELINA randomized trial［J］.Diabetes Care,2019,42(10):1930-1938.
［18］　王晞.肾衰宁颗粒联合沙格列汀治疗糖尿病肾病的临床研究［J］.现代药物与临床,2017,32(5):884-887.
WANG X.Clinical study on Shenshuaining Granules combined with saxagliptin in treatment of diabetic nephropathy［J］.Drugs Clin,2017,32(5):884-887.

相似文献/References:

[1]张秀敏.带蒂大网膜—脑移植术治疗缺血性脑卒中的护理[J].新乡医学院学报,1985,2(02):010.
[2]宋伟。 蔺志清,夏国庆,遣燕燕.超早期选择性动脉溶栓治疗急性缺血性脑卒中13例[J].新乡医学院学报,2002,19(06):496.
[3]翁孝刚.2型糖尿病与胰岛B一细胞功能[J].新乡医学院学报,2002,19(03):231.
[4]汪裕荣.血脂康联合小剂量阿司匹林治疗2型糖尿病并高脂血症的长期疗效观察[J].新乡医学院学报,2002,19(05):391.
[5]型糖尿病合并高血压的胰岛素敏感性探讨.2型糖尿病合并高血压的胰岛素敏感性探讨[J].新乡医学院学报,2003,20(02):124.
[6]何伟玺.冠心病与2型糖尿病患者心率变异性对比分析[J].新乡医学院学报,2003,20(04):282.
[7]李万森,毛向莹,邱培勇.2型糖尿病合并脑梗死50例临床分析[J].新乡医学院学报,2003,20(05):353.
[8]殷国田,崔瑞花.益津降糖胶囊治疗2型糖尿病42例[J].新乡医学院学报,2003,20(05):372.
[9]新乡市第二人民医院内分泌科 河南新乡.依那普利对2型糖尿病合并高血压患者血压及胰岛素敏感性指数的影响[J].新乡医学院学报,2005,22(03):267.
[10]刘大建,赵美英,贺维亚,等.缺血性脑卒中患者颅外段颈动脉狭窄的临床特点及危险因素 [J].新乡医学院学报,2007,24(04):370.

更新日期/Last Update: 2022-12-05